ARHGAP29

Chr 1p22.1

Rho GTPase activating protein 29

Aliases:: PARG1
MANE:: ENST00000260526.11

OMIM: 610496 ↗NCBI: 9411 ↗Ensembl ↗

Annotations refreshed 9 hours ago.

Predicted protein structure

AlphaFold predicted structure

ARHGAP29 · Q52LW3

v62025-08-01

Predicted Aligned Error matrix for ARHGAP29 — diagonal shows residue index, colour shows pairwise prediction confidence (lower is better) — Predicted Aligned Error

Mean pLDDT

63.7/ 100

Low

1,261 residues

Confidence breakdown

Very high(≥ 90)38%
Confident(70–90)13%
Low(50–70)4%
Very low(< 50)46%

Open interactive 3D viewer

AlphaFold (Jumper et al., 2021) · CC BY 4.0

Clinical relevance (Genomics England PanelApp)

Diagnostic Grade (Green)

Clefting
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Fetal anomalies
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown

Disease associations (Open Targets)

cleft palate
0.62
cleft lip
0.61
orofacial cleft
0.49
neurodegenerative disease
0.35
hypertensive disorder
0.32
breast carcinoma
0.31
alcohol drinking
0.31
Hepatitis
0.30
essential hypertension
0.28
drug allergy
0.26

Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.

Protein function (UniProt)

Rho GTPase-activating protein 29

GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state. Has strong activity toward RHOA, and weaker activity toward RAC1 and CDC42. May act as a specific effector of RAP2A to regulate Rho. In concert with RASIP1, suppresses RhoA signaling and dampens ROCK and MYH9 activities in endothelial cells and plays an essential role in blood vessel tubulogenesis